2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1575

The Association between Salivary Gland Ultrasonography and Clinical Manifestation in Patients with Early Primary Sjögren’s Syndrome
Abstract Number: 1576

Soluble Semaphorin 4D/CD100 Is Increased in the Saliva of Sjögren’s Syndrome
Abstract Number: 1577

Soluble Siglec-5 Is a Novel Salivary Biomarker for Primary Sjogren’s Syndrome
Abstract Number: 1578

Exercise Increases Aerobic Capacity in Primary Sjögren´s Syndrome: A Randomized Controlled Trial
Abstract Number: 1579

Sjögren’s Syndrome Is Associated with Reduced Sex Hormone Exposure: A Case-Control Study
Abstract Number: 1580

Persistent Serological Activity in Primary Sjögren’s Syndrome
Abstract Number: 1581

Lack of Specificity in Testing for Murine Tissue Specific Autoantibodies for the Diagnosis of Sjogren’s Syndrome
Abstract Number: 1582

Clinical Correlations and Expression Pattern of the Autoimmunity Susceptibility Factor Diora-1 in Primary Sjögren’s Syndrome
Abstract Number: 1583

Low-Dose IL-2 Promotes the Proliferation of Peripheral Regulatory T Cells in Primary Sjogren’s Syndrome to Restore Its Balances with Pro-Inflammatory Lymphocytes
Abstract Number: 1584

Evaluation of the Performance of the 2016 American College of Rheumatology-European League Against Rheumatism (Acr-Eular) Classification Criteria for Primary Sjogren`S Syndrome in Different Centers of Argentina
Abstract Number: 1585

Primary Sjögren’s Syndrome Stratification Based on the Severity of Patient-Reported Fatigue
Abstract Number: 1586

Expression of JAK Proteins and Autophagy Markers in Sjögren’s Syndrome Patients
Abstract Number: 1587

Pathogenic Role of Interleukin 27 in the Nonobese Diabetic Mouse Model of Sjögren Syndrome
Abstract Number: 1588

Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in the Province of British Columbia
Abstract Number: 1589

Cardiac Biomarkers and Carotid Atherosclerosis and Its Progression in Psoriatic Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].